In previously treated
Ph+ CML in chronic phase
Some people with Ph+ CML in chronic phase may need to switch treatments—and SCEMBLIX may be an option
If you've taken another tyrosine kinase inhibitor (TKI) previously but the treatment hasn't worked as hoped, it may be time to ask your doctor about SCEMBLIX.
In a head-to-head clinical study of patients with Ph+ CML-CP previously treated with ≥ 2 TKIs:
More patients achieved MMR with SCEMBLIX vs Bosulif at 24 weeks
SCEMBLIX is the only treatment for Ph+ CML in chronic phase to show superior efficacy, such as response rates, vs Bosulif * in a clinical trial.
In a clinical study among those who did not respond to or did not tolerate 2 or more prior TKIs for Ph+ CML in chronic phase:
Nearly twice as many patients achieved a major molecular response (MMR) with SCEMBLIX at 24 weeks than with Bosulif. The results were 25% for SCEMBLIX (40 of 157 patients) vs 13% for Bosulif (10 of 76 patients).
*Bosulif is a registered trademark of Pfizer Inc
Nearly 40% of patients achieved MMR at 96 weeks
In the same clinical study among patients with Ph+ CML in chronic phase who were previously treated with 2 or more TKIs:
More than twice as many patients achieved MMR with SCEMBLIX at nearly 2 years (96 weeks) than with Bosulif. The results were 38% for SCEMBLIX (59 of 157 patients) vs 16% for Bosulif (12 of 76 patients).
In this clinical trial, the most common side effects reported (≥ 20%) with SCEMBLIX were nose/throat infections; pain in the muscles, bones, or joints; headache; and tiredness.
Three times fewer SCEMBLIX patients stopped treatment due to side effects
In the same clinical study, more patients taking SCEMBLIX were able to continue their treatment than those taking Bosulif. After nearly 2 years (96 weeks), 26% of patients taking Bosulif (20 of 76 patients) had to stop taking their medication due to side effects compared to 8% of those taking SCEMBLIX (12 of 156 patients).
 | Talk with your doctor about SCEMBLIXWhen you have Ph+ CML in chronic phase, it’s important to be your own advocate. To help you have a productive conversation, download the Doctor Discussion Guide. |
Common side effects of SCEMBLIX
The most common side effects of SCEMBLIX include muscle, bone, or joint pain; rash; tiredness; nose, throat, or sinus (upper respiratory tract) infections; headache; stomach-area (abdominal) pain; diarrhea; decreased white blood cell counts, platelet counts, and red blood cell counts; decreased blood calcium corrected levels; increased blood pancreas enzyme (lipase and amylase) levels; increased blood fat (cholesterol and triglycerides) levels; increased blood uric acid levels; increased blood liver enzyme levels; increased blood alkaline phosphatase levels; and increased blood creatine kinase levels.
Your doctor may change your dose, temporarily stop, or permanently stop treatment with SCEMBLIX if you have certain side effects.
SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your doctor if this is a concern for you.
Be sure to review information about the serious and most common side effects of SCEMBLIX. Learn more
